Obesity in adult patients with inflammatory bowel disease: Clinical features and impact on disability. A cross-sectional survey from the GETAID

Autor: Rose Al Bacha, Yoram Bouhnik, Melanie Serrero, Jerome Filippi, Xavier Roblin, Anne Bourrier, Guillaume Bouguen, Denis Franchimont, Guillaume Savoye, Anthony Buisson, Edouard Louis, Stephane Nancey, Vered Abitbol, Jean-Marie Reimund, Olivier DeWit, Lucine Vuitton, Nicolas Mathieu, Laurent Peyrin-Biroulet, Cyrielle Gilletta, Matthieu Allez, Stephanie Viennot, Catherine Le Berre, David Laharie, Maria Nachury, Aurelien Amiot, Sara Tadbiri, Charlotte Gagniere, Jenny Tannoury, Benjamin Pariente, Pauline Wils, Carmen Stefanescu, Xavier Treton, Carole Martins, Mathieu Uzzan, Xavier Hébuterne, Nadia Arab, Virginie Cluzeau, Emilie Del Tedesco, Laurent Beaugerie, Philippe Seksik, Cecilia Landmann, Julien Kirchgesner, Harry Sokol, Laurent Siproudhis, Marie DeWitte, Catherine Reenaers, Gilles Boschetti, Claire Gay, Pauline Danion, Bernard Flourié, Georgia Malamut, Benedicte Caron, Olivier DeWitt, Sandie Pestour, Thomas Chateau, Camille Zallot, Jean-Marc Gornet, Clotilde Baudry, Arnaud Bourreille, Caroline Trang-Poisson, Nina Dib, Hedi Brixi, Guillaume Cadiot, Medina Boualit, Claire Painchart, Laurianne Plastaras, Romain Altwegg, Lucile Boivineau, Mathurin Fumery, Ludovic Caillo, Pauline Riviere, Florian Poullenot, Benoit Coffin, Henri Duboc, Stephane Nahon, Noemie Tavernier, Marion Simon, Baya Coulibaly, Morgane Amil, Duveau Nicolas, Sherine Khater, Mehdi Kaassis, Felix Goutorbe, Driffa Moussata, Laurence Picon

Publikováno v: Digestive and Liver Disease
Digestive and Liver Disease, 2023, ⟨10.1016/j.dld.2023.05.008⟩

International audience; Background: In recent years, an increasing prevalence of obesity in inflammatory bowel disease (IBD) has been observed. However, only a few studies have focused on the impact of overweight and obesity on IBD-related disability

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7063a4a36cbe10970704f3ac0d172dc9
https://doi.org/10.1016/j.dld.2023.05.008

Effectiveness and Safety of Subcutaneous Rituximab for Patients With Gastric MALT Lymphoma: A Case–Control Comparison With Intravenous Rituximab

Autor: K. Belhadj, Corinne Haioun, Muriel Verlinde-Carvalho, Aurelien Amiot, Charlotte Gagniere, Iradj Sobhani, Emmanuel Itti, Jehan Dupuis, Jenny Tannoury, Christiane Copie-Bergman, Hugo Rotkopf, Fabien Le Bras, Michael Levy

Publikováno v: Clinical Lymphoma Myeloma and Leukemia. 21:e32-e38

Introduction Rituximab is a standard treatment for gastric mucosa-associated lymphoid tissue (MALT) lymphoma (GML). We sought to compare the effectiveness and safety of subcutaneous and intravenous rituximab in a retrospective case–control study. P

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5317d5de4fa8631a418f561c83cb9506
https://doi.org/10.1016/j.clml.2020.08.014

Patients’ real-world experience with inflammatory bowel disease: A cross-sectional survey in tertiary care centres from the GETAID group

Autor: Maria Nachury, Yoram Bouhnik, Melanie Serrero, Jerome Filippi, Xavier Roblin, Julien Kirchgesner, Guillaume Bouguen, Denis Franchimont, Guillaume Savoye, Anthony Buisson, Edouard Louis, Stephane Nancey, Vered Abitbol, Jean-Marie Reimund, Olivier DeWit, Lucine Vuitton, Nicolas Matthieu, Laurent Peyrin-Biroulet, Cyrielle Gilletta, Sara Tadbiri, Matthieu Allez, Stephanie Viennot, Arnaud Bourreille, David Laharie, Aurelien Amiot, Charlotte Gagniere, Jenny Tannoury, Benjamin Pariente, Pauline Wils, Carmen Stefanescu, Xavier Treton, Xavier Hébuterne, Nadia Arab, Virginie Cluzeau, Emilie Del Tedesco, Laurent Beaugerie, Philippe Seksik, Anne Bourrier, Cecilia Landmann, Harry Sokol, Laurent Siproudhis, Marie DeWitte, Catherine Reenaers, Gilles Boschetti, Claire Gay, Pauline Danion, Bernard Flourié, Georgia Malamut, Benedicte Caron, Olivier DeWitt, Nicolas Mathieu, Sandie Pestour, Camille Zallot, Jean-Marc Gornet, Clotilde Baudry, Caroline Trang-Poisson, Nina Dib, Hedi Brixi, Guillaume Cadiot, Medina Boualit, Claire Painchart, Laurianne Plastaras, Romain Altwegg, Lucile Boivineau, Mathurin Fumery, Ludovic Caillo, Pauline Riviere, Florian Poullenot, Benoit Coffin, Henri Duboc, Stephane Nahon, Noemie Tavernier, Marion Simon, Baya Coulibaly, Morgane Amil, Duveau Nicolas, Sherine Khater, Mehdi Kaassis, Felix Goutorbe, Driffa Moussata, Laurence Picon

Publikováno v: Digestive and Liver Disease
Digestive and Liver Disease, 2021, 53 (4), pp.434-441. ⟨10.1016/j.dld.2020.10.020⟩
Digestive and Liver Disease, WB Saunders, 2021, 53 (4), pp.434-441. ⟨10.1016/j.dld.2020.10.020⟩
Digestive and liver disease, Vol. 53, no.4, p. 434-441 (2021)
Digestive and Liver Disease, Elsevier, 2021, 53 (4), pp.434-441. ⟨10.1016/j.dld.2020.10.020⟩

International audience; BACKGROUND: Patients’ experience with healthcare professionals could influence their clinical outcomes. AIMS: To assess inflammatory bowel disease (IBD) patients’ experience with their disease, their treatment and their re

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8568cc4cd662f66fe823e34ee32bceb9
https://hal.science/hal-03038260

Editorial: determining disability in inflammatory bowel disease-'See(k) and you shall find'. Authors' reply

Autor: Aurelien Amiot, Jenny Tannoury

Publikováno v: Alimentary pharmacologytherapeuticsREFERENCES. 53(12)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::152fac76d8770c5fa1b8e3f1ba60fd27
https://pubmed.ncbi.nlm.nih.gov/34029415

Patients’ perspectives after switching from infliximab to biosimilar CT-P13 in patients with inflammatory bowel disease: A 12-month prospective cohort study

Autor: Hugo Rotkopf, Farida Mesli, Francesco Brunetti, Jenny Tannoury, Nicolas Petitdidier, Nicola de’Angelis, Charlotte Gagniere, Iradj Sobhani, Aurelien Amiot, Anne Hulin

Publikováno v: Digestive and Liver Disease
Digestive and Liver Disease, WB Saunders, 2019, 51, pp.1652-1660. ⟨10.1016/j.dld.2019.08.020⟩
Digestive and Liver Disease, Elsevier, 2019, 51, pp.1652-1660. ⟨10.1016/j.dld.2019.08.020⟩

Background Patients’ perspectives after switching from infliximab to a biosimilar have yet to be assessed. Aim To assess patients’ perspectives in a prospective manner after switching from infliximab to CT-P13. Methods 113 consecutive patients wi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a59aa96f4de594946d0981b2e638d81
https://hal.archives-ouvertes.fr/hal-03489097